A press release by GlaxoSmithKline in February 2007 noted that there is a greater incidence of fractures of the upper arms, hands and feet in female diabetics given rosiglitazone compared with those given metformin or glyburide. The information was based on data from the ADOPT trial. Following release of this statement, Takeda Pharmaceutical Company, the developer of<unk>  (sold as Actos in many markets) admitted that it has similar implications for female patients. The risk of hypoglycemia is low in the absence of other drugs that lower blood glucose.<unk>  can cause fluid retention and peripheral edema. As a result, it may precipitate congestive heart failure (which worsens with fluid overload in those at risk). It may cause anemia. Mild weight gain is common due to increase in subcutaneous adipose tissue. In studies, patients on<unk>  had an increased proportion of upper respiratory tract infection, sinusitis, headache, myalgia and tooth problems. Chronic administration of the drug has led to occasional instances of cholestatic hepatitis, reversible upon drug discontinuation. On July 30, 2007 an Advisory Committee of the Food and Drug Administration concluded that the use of rosiglitazone for the treatment of type 2 diabetes was associated with a greater risk of "myocardial ischemic events" when compared to placebo, but when compared to other diabetes drugs, there was no increased risk.<unk>  is currently being reviewed. A meta-analysis released subsequently showed that<unk>  reduced the risk of ischemic cardiac events rather than increased the risk, but increased CHF. Bladder cancer On June 9, 2011, the French Agency for the Safety of Health Products decided to withdraw<unk>  due to high risk of bladder cancer. This suspension was based on the results of an epidemiological study conducted by the French National Health Insurance. According to the results of the epidemiological study, the French agency found that patients, who were taking Actos for a long time to aid in type 2 diabetes mellitus, significantly increased risk of bladder cancer compared with patients who were taking other diabetes medications. On June 10, 2011 Germany's Federal Institute for Drugs and Medical Devices also advised doctors not to prescribe the medication until further investigation of the cancer risk had been conducted. On June 15, 2011, the U.S. FDA announced that<unk>  use for more than one year may be associated with an increased risk of bladder cancer, and two months later the label was updated with an additional warning about this risk. A 2017 meta-analysis found no difference in the rates of bladder cancer attributed to the<unk> .
Pioglitazone
Rosiglitazone
Liraglutide
Linagliptin
Acarbose
Vildagliptin
Glibenclamide
Metformin